XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue and Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Net Revenue by Organ and Country

The Company disaggregates revenue from contracts with customers related to OCS transplant by organ type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

OCS transplant revenue by country
  by organ(1)(2):

 

 

 

 

 

 

United States

 

 

 

 

 

 

Lung total revenue

 

$

3,636

 

 

$

4,706

 

Heart total revenue

 

 

26,266

 

 

 

20,224

 

Liver total revenue

 

 

108,715

 

 

 

66,926

 

Total United States OCS
  transplant revenue

 

 

138,617

 

 

 

91,856

 

All other countries

 

 

 

 

 

 

Lung revenue

 

 

375

 

 

 

960

 

Heart revenue

 

 

3,550

 

 

 

3,131

 

Liver revenue

 

 

140

 

 

 

 

Total all other countries OCS
  transplant revenue

 

 

4,065

 

 

 

4,091

 

Total OCS transplant revenue

 

$

142,682

 

 

$

95,947

 

(1)
Revenue by country is categorized based on the location of the end customer. Total OCS transplant revenue includes product and service revenue.
(2)
Service revenue unrelated to OCS transplant, which was $0.9 million for each of the three months ended March 31, 2025 and 2024, is not included in this table.
Summary of Significant Segment Expenses Significant segment expenses, as provided to the CODM, are presented below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Total revenue

 

$

143,537

 

 

$

96,850

 

Less:

 

 

 

 

 

 

Cost of net product revenue

 

 

16,312

 

 

 

14,084

 

Cost of service revenue

 

 

38,997

 

 

 

22,804

 

Research, development and clinical trials:

 

 

 

 

 

 

Personnel related (including stock-based
   compensation expense)

 

 

6,252

 

 

 

5,264

 

Laboratory supplies and research materials

 

 

4,956

 

 

 

2,314

 

Consulting and third-party services

 

 

4,173

 

 

 

2,007

 

Clinical trials costs

 

 

81

 

 

 

82

 

Facility related and other

 

 

1,698

 

 

 

1,713

 

Selling, general and administrative:

 

 

 

 

 

 

Personnel related (including stock-based
   compensation expense)

 

 

27,671

 

 

 

24,387

 

Professional and consultant fees

 

 

7,558

 

 

 

3,765

 

NOP support

 

 

2,406

 

 

 

1,962

 

Tradeshows and conferences

 

 

426

 

 

 

983

 

Facility related and other

 

 

5,564

 

 

 

5,064

 

Other segment items(1)

 

 

1,761

 

 

 

224

 

Net income

 

$

25,682

 

 

$

12,197

 

(1) Other segment items include interest income, interest expense, foreign currency exchange gains and losses and income taxes. See the condensed consolidated financial statements for other financial information regarding the Company’s operating segment.